PresentationGood day, and welcome to the Molecular Partners call and webcast. [Operator Instructions] As a reminder, this call may be recorded. I would now like to turn the call over to Seth Lewis, Head of Investor Relations and Strategy. Please go ahead.Seth LewisSenior Vice President of Investor Relations, Communications & Strategy Thank you and welcome to today's call. My name is Seth Lewis, Head of Investor Relations and Strategy. And this morning, we're following up on the data presented this weekend a ...

Molecular Partners (NasdaqGS:MOLN) Update / briefing February 02, 2026 08:00 AM ET Company ParticipantsKen Herrmann - Chairman of the Scientific Advisory BoardMichael Stumpp - EVP of ProjectsPatrick Amstutz - CEOPhilippe Legenne - CMOSeth Lewis - Head of Investor Relations and StrategyConference Call ParticipantsAlbert Agustinus - AnalystBill Maughan - AnalystCharles Zhu - AnalystChiara Montironi - AnalystGeorg Zimmermann - AnalystMichael Nedelcovych - Senior Equity AnalystOperatorGood day, and welcome to t ...

Progressing the first Radio-DARPin Therapeutic MP0712 (212Pb x DLL3) for SCLC into the clinic ➢New patient imaging and dosimetry data ➢Update on Phase 1/2a study Patrick Amstutz, CEO Webcast call following TWC 2026 presentation February 2, 2026 Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of ...

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Clinical Development - The data from five evaluable patients show favorable tumor uptake of MP0712 with limited uptake in healthy tissues, supporting its therapeutic potential [2][3] - The biodistribution and dosimetry data validate the ongoing U.S. Phase 1/2a study of MP0712, which aims to assess safety and determine a recommended phase 2 dose [4][5] Presentation Details - Two posters and an oral presentation were made at the congress, highlighting the specific tumor accumulation and dosimetry data that support the clinical development of MP0712 [5][7] - The oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was scheduled for January 31, 2026, focusing on the progress of MP0712 [7] Future Outlook - Initial clinical data from the Phase 1/2a study of MP0712 is expected in 2026, with the company planning to share safety and activity data as the study progresses [4][5] - The company aims to establish itself as a leader in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4]

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Group 1: Clinical Development - The data from five evaluable patients support the clinical development plans for MP0712, which utilizes the therapeutic isotope 212Pb [2][4] - The biodistribution of MP0712 shows specific tumor uptake with limited accumulation in healthy tissues, reinforcing its therapeutic potential [3][4] - The ongoing Phase 1/2a study in the U.S. aims to assess safety and determine a recommended phase 2 dose for MP0712, with initial clinical data expected in 2026 [4][5] Group 2: Presentation Details - The data was presented through two posters and an oral presentation at the Theranostics World Congress, highlighting the favorable distribution profile and dosimetry data of MP0712 [2][5] - An oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was conducted, showcasing the progress of MP0712 [7] Group 3: Company Strategy and Future Outlook - The CEO of Molecular Partners expressed optimism about the data, emphasizing the company's ambition to lead in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4] - The company plans to share initial Phase 1 safety and activity data in 2026 as it advances its Radio-DARPin platform [4][5] - Molecular Partners' Radio-DARPins are designed to address limitations of traditional radioligand therapy, enhancing tumor uptake while minimizing toxicity [9][10]

Core Insights - The presentation at the JPMorgan Healthcare Conference indicates a renewed confidence in the biotech sector, with expectations for a turnaround by 2026 [2] - Aktis Oncology's successful IPO has positively impacted the radiotherapy field, generating increased interest and engagement [3] Company Insights - Molecular Partners is focusing on radiotherapy as a key area of interest, reflecting the broader trends in the biotech industry [3] - The company acknowledges the role of Aktis Oncology in revitalizing the IPO market, which is crucial for attracting investment in biotech [3]

Summary of Molecular Partners FY Conference Call Company Overview - **Company Name**: Molecular Partners (NasdaqGS:MOLN) - **Focus**: Development of DARPin candidates, particularly in the field of radiotherapy - **Financial Position**: Over $100 million in cash (approximately CHF 93 million) available for investment in R&D [4][30] Key Industry Insights - **Biotech Sector Outlook**: Increased confidence in a turnaround for the biotech sector in 2026, following a challenging period [3] - **Radiotherapy Market**: Positive feedback and renewed interest in radiotherapy, highlighted by the successful IPO of Aktis Oncology [3] Core Product Focus - **Primary Candidate**: MP0712, a DLL3-targeted DARPin, is expected to drive value creation in the upcoming year [4][6] - **Pipeline Overview**: Emphasis on MP0712, with additional focus on MPO 317 and MPO 533, which are also in development [6][11] Product Development and Clinical Trials - **MPO 317**: Initially considered a dead program, it has been revived due to promising phase one data showing immune activation in colorectal carcinoma. A new trial will involve 75 patients across 11 centers in France, with results expected in 2027 [10][11] - **MPO 533**: A multispecific DARPin targeting acute myeloid leukemia (AML), designed to eradicate residual disease clones. The focus will be on low disease burden patients [11][12] Radiotherapy Mechanism - **Mechanism of Action**: MP0712 utilizes a DARPin vector linked to a radioisotope (Lead-212) to target DLL3 in small cell lung cancer. The approach aims to combine the efficacy of T cell engagers with the durability of antibody-drug conjugates (ADCs) [14][16][18] - **Clinical Strategy**: The company plans to initiate a phase one dose escalation trial, starting with a 75-megabecquerel dose, with a fast-to-market strategy for small cell lung cancer [27][30] Safety and Efficacy Considerations - **Safety Profile**: The rapid decay of Lead-212 is expected to result in minimal hematological toxicity, with recovery of blood values anticipated [34][37] - **Patient Experience**: Radiotherapy is expected to offer a better quality of life for patients compared to T cell engagers, which often cause acute side effects [37] Partnerships and Collaborations - **Orano Med Partnership**: A 50/50 partnership focused on the supply of Lead-212, with Orano Med providing a robust supply chain and infrastructure for the isotope [40][43] - **Future Collaborations**: The company is open to exploring partnerships for other isotopes, such as actinium, to enhance treatment options [45][46] Future Directions - **Expansion of Indications**: Beyond small cell lung cancer, there are plans to explore other neuroendocrine tumors with DLL3 expression [47][48] - **Innovative Imaging Techniques**: The use of imaging agents to select patients with DLL3 expression is seen as pivotal for maximizing treatment efficacy [48] Conclusion - **Focus for 2026**: The primary focus will be on MP0712, with expectations for first-in-human results and safety data in the first half of the year, followed by activity data in the second half [30]

Company Overview - Molecular Partners is a clinical-stage biotech company founded in 2004, with operations and listings in Switzerland (SIX, 2014) and the US (Nasdaq, 2021)[12] - The company is financed with approximately USD 116 million / CHF 93 million to reach upcoming value inflection points[12] - Molecular Partners focuses on oncology with differentiated assets like MP0712 (targeted radiotherapy) and MP0533 (next-gen immune cell engagers)[12] Radio-DARPin Therapeutics (RDT) - The company is developing Radio-DARPin therapeutics, which are designed for precise delivery of potent radio-isotopes to tumors[26, 27] - Molecular Partners has a global partnership with Orano Med to develop 212Pb Radio-DARPin therapeutics, with a 50:50 cost and share split for 4 programs[33, 36] - MP0712, a 212Pb x DLL3 Radio-DARPin, is in Phase 1/2a clinical trials in the US for small cell lung cancer (SCLC) and other neuroendocrine cancers (NECs), with early data expected in 2026[43, 77] - Preclinical data for MP0712 shows high tumor accumulation (Tumor > Kidney) and reduction of established tumors in mice[51] - MP0726, a 212Pb x MSLN Radio-DARPin, is being developed for ovarian cancer and is progressing towards first-in-human (FIH) imaging[86, 94] Other Pipeline Programs - MP0317, a FAP-localized CD40 agonist, is in a Phase 2 combo study in advanced biliary tract cancer, with interim analysis expected by YE 2027[104, 117, 123] - MP0533, a tetra-specific T-cell engager for AML, is in Phase 1/2a, with decisional data expected in H1 2026[124] - The company is developing Switch-DARPin platform for next-generation T cell engagers, with a lead candidate selection expected in H1 2026 and an update at AACR 2026[99, 140] Financial Outlook - The company's cash of approximately USD 116 million (CHF 93 million) ensures funding until 2028[99]

Core Insights - Molecular Partners AG is advancing its clinical-stage pipeline of DARPin therapeutics, focusing on targeted radiotherapy and immune cell engagers, with significant milestones expected in 2026 [1][20]. Financial Overview - As of December 31, 2025, the company reported cash and cash equivalents of CHF 93.1 million, sufficient to fund operations until 2028 [3]. Clinical Development Updates - The Phase 1/2a trial for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer (SCLC), has commenced, with initial patient dosing expected in Q1 2026 and initial clinical data anticipated in the same year [2][4][7]. - MP0726, another Radio-DARPin targeting mesothelin (MSLN) for ovarian cancer, is also in development, with preclinical data presented at the 2025 SNMMI meeting [6]. - An investigator-initiated Phase 2 trial for MP0317 in cholangiocarcinoma is ongoing, with the first patient treated in early 2026 [10][11]. - MP0533, a tetra-specific T cell engager for acute myeloid leukemia (AML), is in a Phase 1/2a trial, with updates on its clinical development expected in H1 2026 [12][14]. Scientific Advisory Board - The formation of a scientific advisory board, chaired by Prof. Ken Herrmann, aims to accelerate the development of targeted radiotherapeutics [8]. DARPin Technology - Molecular Partners' DARPin therapeutics are designed for high specificity and stability, enabling effective delivery of radioactive payloads to tumors while minimizing damage to healthy tissues [19].

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs aimed at addressing medical challenges that other drug modalities cannot effectively tackle [3] Group 1: Company Overview - Molecular Partners AG is listed on both SIX and NASDAQ under the ticker MOLN and was founded in 2004 [3] - The company has its headquarters in Zurich, Switzerland, and an office in Concord, Massachusetts, USA [3] - The primary focus of the company is oncology, with various programs in different stages of pre-clinical and clinical development [3] Group 2: Upcoming Events - The CEO, Patrick Amstutz, will present the latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2025, from 10:30 AM to 11:10 AM PT [2] - A webcast of the presentation will be available on the Molecular Partners website under the Events tab [2] Group 3: Strategic Partnerships - Molecular Partners collaborates with leading pharmaceutical companies to leverage the advantages of DARPins and provide unique solutions to patients [3]